Company Reports Q1 Revenue of $724K, Up 84% YoY
Reports Q1 revenue $724K vs. $393K y/y. The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. Balance Sheet
Trade with 70% Backtested Accuracy
Analyst Views on TXMD
About TXMD
About the author
Therapeutics MD Reports Improved Financials for FY 2025
- Improved Net Loss: Therapeutics MD reported a net loss from continuing operations of $0.7 million for FY 2025, translating to a loss of $0.06 per basic and diluted share, which is an improvement of $1.7 million compared to a net loss of $2.3 million in FY 2024, indicating positive progress in financial health.
- License Revenue Growth: The company generated $3.0 million in license revenue from continuing operations in FY 2025, an increase of $1.3 million or 71.6% from $1.8 million in FY 2024, primarily driven by increased sales of licensed products under the Mayne License Agreement, showcasing successful market expansion efforts.
- Decrease in Operating Expenses: Total operating expenses for FY 2025 were $7.4 million, down $0.5 million or 5.9% from $7.9 million in FY 2024, mainly due to lower impairment charges recognized in 2025, although this was partially offset by higher bonus expenses and increased investor communication costs.
- Cash Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $7.5 million, indicating a strong liquidity position that supports future operations and investments.
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
TherapeuticsMD Swings to Profit in Q2
Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.
Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.
TherapeuticsMD Q2 Earnings Summary
Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.
Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Market Overview: The Dow Jones index rose over 450 points, indicating positive market sentiment, while insider trading activities in penny stocks reflect investor confidence or concerns regarding company prospects.
Recent Insider Transactions: Notable insider purchases include System1's Cee Holdings Trust acquiring shares after strong earnings, TherapeuticsMD's director buying shares following a quarterly loss, and Ault Alliance's executive purchasing shares amid dividend announcements.
Therapeutics MD Reports Improved Financials for FY 2025
- Improved Net Loss: Therapeutics MD reported a net loss from continuing operations of $0.7 million for FY 2025, translating to a loss of $0.06 per basic and diluted share, which is an improvement of $1.7 million compared to a net loss of $2.3 million in FY 2024, indicating positive progress in financial health.
- License Revenue Growth: The company generated $3.0 million in license revenue from continuing operations in FY 2025, an increase of $1.3 million or 71.6% from $1.8 million in FY 2024, primarily driven by increased sales of licensed products under the Mayne License Agreement, showcasing successful market expansion efforts.
- Decrease in Operating Expenses: Total operating expenses for FY 2025 were $7.4 million, down $0.5 million or 5.9% from $7.9 million in FY 2024, mainly due to lower impairment charges recognized in 2025, although this was partially offset by higher bonus expenses and increased investor communication costs.
- Cash Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $7.5 million, indicating a strong liquidity position that supports future operations and investments.
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
TherapeuticsMD Swings to Profit in Q2
Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.
Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.
TherapeuticsMD Q2 Earnings Summary
Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.
Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Market Overview: The Dow Jones index rose over 450 points, indicating positive market sentiment, while insider trading activities in penny stocks reflect investor confidence or concerns regarding company prospects.
Recent Insider Transactions: Notable insider purchases include System1's Cee Holdings Trust acquiring shares after strong earnings, TherapeuticsMD's director buying shares following a quarterly loss, and Ault Alliance's executive purchasing shares amid dividend announcements.
